TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| BioHelix goes out on its own, joins Beverly cluster New England Biolabs spinoff BioHelix Corp. is leaving the nest and establishing its own headquarters after five years under its parent’s wing. feeds.bizjournals.com |
Investing in the Obesity Drug Basket Michael Murphy submits:For many years, the Department of Agriculture has published a food triangle that recommends carbohydrates as the basis of a healthy diet, even though there is no minimum daily requirement for carbs. None. Dr. Atkins is rolling over in his grave. Complete Story » seekingalpha.com |
A N.I.C.E. Development for Generex Oral-lyn in the U.K. R.J Steffens submits:The United Kingdom's National Institute for Health and Clinical Excellence (NICE) has recently begun the draft scope for the official Health Technology Appraisal of Generex's (GNBT) novel buccal insulin for the management of type 1 diabetes. Oral-lyn is not yet licensed for sale in the UK. Oral-lyn is in Phase III trials for patients with Type 1 diabetes and Generex is consequently moving closer towards submission to the Medicines and Healthcare products Regulatory Agency MHRA. At present, over 350 patients have been enrolled in the Phase III program at 70 clinical sites around the world.NICE produces guidance on public health, health technologies and clinical practice for England, Wales, Northern Ireland and Scotland. These are recommendations, based on the best available evidence, on the appropriate treatment and care of people with specific diseases and conditions. NICE does not license drugs or devices. Licensing drugs and devices in the UK is done by MHRA. A recommendation by NICE ends any uncertainty and inequality about prescribing. Once national guidance has been issued by NICE, it replaces local recommendations.Complete Story » seekingalpha.com |
Cord Blood America Announces Debt Down; Gross Margins Up: Balance Sheet Significantly Improved (PR Newswire) Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that its 10Q filing with the U.S. us.rd.yahoo.com |
Human Genome Sciences Looks Ready to Break Out Trader Mark submits:You may be noticing I've been focusing on a certain type of chart of late, as I see a lot of similar set ups... stocks which have built nice bases and appear ready to break out of them. If indeed this market is ready to burst over S&P 1120, and "melt up" as portfolio managers "mark up" their books for year end, these stocks with huge bases built should become real stars. A reader just sent me Human Genome Sciences (HGSI), a $5B market cap biotech company working on a lupus drug, which has a 2 month base built. Complete Story » seekingalpha.com |